Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

Phase 2

Terminated

• Conditions: Cancer of the Prostate
• Interventions: Drug: BHR-200 (0.36% transdermal 17β-estradiol gel); Drug: Placebo

• Registration Number: NCT02349386
• Lead Sponsor: BHR Pharma, LLC

Brief Summary

The objective of this clinical study is to evaluate the safety and efficacy of three different doses of BHR-200 (0.36% transdermal estradiol gel) compared to placebo for the maintenance of testosterone (T) suppression in men with advanced androgen-sensitive prostate cancer.

Detailed Description

This is a multi-center, randomized, double-blind, placebo-controlled, dose finding study in men with advanced androgen-sensitive prostate cancer. Patients who give informed consent will have screening evaluations, and if fulfilling the entry criteria, will be randomized to one of 4 treatment groups: 1mL, 2mL or 3mL of 0.36% BHR-200 (transdermal estradiol gel) or Placebo. Study drug will be initiated on the day they were scheduled to receive next depot GnRH agonist injection. Patients will be offered low-dose radiation to aid in the prevention of gynecomastia. Patients will apply the study drug once per day. The first dose of study gel will be applied under the supervision of the PI/designee. Subsequent doses will be self-administered daily by the patient until he is no longer chemically castrated (testosterone levels increase above 50 ng/dL), a rise over baseline PSA of \> 0.5 ng/mL is observed, or he has completed 52 weeks of study drug administration. At the conclusion of study participation, patients will be advised to resume standard of care treatment under the supervision of their healthcare provider. While on treatment, patients will be evaluated at Day 1 and every 2 weeks, for the first 24 weeks and every 4 weeks thereafter with a final post-treatment follow-up visit 2 weeks (+/- 1 week) post last dose administration.

Study Timeline

• Study First Submitted: 2015-01-23
• Study First Submitted QC: 2015-01-27
• Study First Posted: 2015-01-28
• Study Start: 2015-07
• Primary Completion: 2017-06-14
• Study Completion: 2018-01-10
• Status Verified: 2018-04
• Results First Submitted: 2021-11-18
• Results First Submitted QC: 2022-03-08
• Last Update Submitted: 2022-03-08
• Results First Posted: 2022-03-31
• Last Update Posted: 2022-03-31

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Male
• Target Recruitment: 34

Inclusion Criteria

1. Males, Ages 18 and older
2. Body Mass Index (BMI) between 18 and 35 kg/m2 (inclusive)
3. Not currently hospitalized
4. Clinical indication of adenocarcinoma of the prostate evidenced by a biopsy report on record
5. At present receiving ADT treatment with a GnRH agonist for at least 2 months but not longer than 36 months without interruption - Note: If the patient received GnRH agonist treatment prior to the treatment described under 5, there must be evidence of a period without GnRH agonist treatment for a minimum of 2 months prior to starting the present treatment as is seen, for example with intermittent treatment regimens.
6. Able to initiate Screening procedures 2 weeks prior to the next scheduled injection with a GnRH agonist
7. Willing to discontinue current ADT regimen for the duration of the study
8. T level less than 50 ng/dL at Screening
9. WHO/ECOG performance status of 0 or 1
10. Life expectancy of at least 1 year
11. Adequate renal function demonstrated by having normal blood urea nitrogen (BUN) and Creatinine Screening lab values

Exclusion Criteria

1. History or presence of allergic or adverse response to estradiol
2. Presence of symptomatic metastatic disease, risk of spinal cord compression or urinary obstruction
3. History within the past 2 years of deep vein thrombosis (DVT), pulmonary embolism (PE2), a known thrombophilic disorder (eg.protein C, protein S, or antithrombin deficiency), or cerebrovascular accident (CVA)
4. History within the past 2 years of myocardial infarction or a coronary vascular procedure (e.g. percutaneous coronary intervention, coronary artery bypass graft)
5. History of congestive heart failure
6. Use of any investigational drug, biologic, or device within 28 days prior to the first dose of study gel
7. Use of any of the following known inducers or inhibitors of cytochrome P450 3A4 (CYP3A4): phenobarbital, carbamazepine, rifampin, erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir, St. John's Wort preparations (Hypericum perforatum), and grapefruit juice
8. Hematological parameters (Hematocrit or Hemoglobin) outside 20% of the upper or lower limits of normal at Screening
9. Active skin rash, sunburn, or other skin disorder on the upper arm(s) that requires treatment or may affect skin absorption of study gel
10. Resting uncontrolled hypertension (HTN) (160/100 mmHg) at Screening
11. Co-existent malignancy or a history of malignancy during the past 5 years, with the exception of basal and/or squamous cell carcinoma of the skin
12. Any other significant concurrent illness or disease or condition that in the opinion of the Investigator might interfere with the patient's ability to receive the treatment outlined in the protocol or might put him at additional risk

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BHR-200 Low Dose	BHR-200 (0.36% transdermal 17β-estradiol gel)	3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
BHR-200 Mid Dose	BHR-200 (0.36% transdermal 17β-estradiol gel)	6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
BHR-200 High Dose	BHR-200 (0.36% transdermal 17β-estradiol gel)	9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
Placebo	Placebo	1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.

Primary Outcome Measures

Name	Time	Method
Maintenance of Testosterone Suppression at Week 12	Week 12	Primary Efficacy Endpoint was the percentage of patients failing to maintain castrate levels of T (T \< 50 ng/dL).; Testosterone suppression, defined as the absence of any T level measurement over 50 ng/dL during Weeks 4 to 12.

Secondary Outcome Measures

Name	Time	Method
Maintenance of Testosterone Suppression at Week 24	Week 24	Pproportion of patients failing to maintaincastrate levels of T (T \< 50 ng/dL). Testosterone suppression, defined as the absence of any T level measurement over 50 ng/dL during Weeks 4 to 24.
Number of Patients Reporting Thromboembolic Adverse Events	To Week 52/End of Study: Both 24-Week Main Study and Optional 28-Week Extension Study	Number of patients and severity of thromboembolic adverse events

Trial Locations

Locations (11)

AccumetRX Clinical Trials; 🇺🇸 Albuquerque, New Mexico, United States

Urologic Consultants of Southeastern Pennsylvania (UCSEPA); 🇺🇸 Bala-Cynwyd, Pennsylvania, United States

Urological Associates of Southern Arizona; 🇺🇸 Tucson, Arizona, United States

Carolina Urologic Research Center; 🇺🇸 Myrtle Beach, South Carolina, United States

Advanced Urology Institute; 🇺🇸 Daytona Beach, Florida, United States

South Florida Medical Research; 🇺🇸 Aventura, Florida, United States

Adult Pediatric Urology, PC; 🇺🇸 Omaha, Nebraska, United States

Eastern Urological Associates; 🇺🇸 Greenville, North Carolina, United States

Delaware Valley Urology; 🇺🇸 Voorhees, New Jersey, United States

Associated Medical Professionals of NY (AMP of NY); 🇺🇸 Syracuse, New York, United States

Urology Clinics of North Texas; 🇺🇸 Dallas, Texas, United States